Assessment of the Relative Bioavailability of Rotigotine 4.5 mg Transdermal Patch Compared to Neupro 2 mg/24 h in Healthy Adult Volunteers Under Fasting Conditions

The primary objective of this study is to evaluate the **bioavailability** of a Rotigotine 4.5 mg (2 mg/24 hrs) transdermal patch compared to the Neupro® 2 mg/24 h transdermal patch in healthy adult volunteers under fasting conditions. This assessment is crucial for determining the relative absorption and systemic availability of the test product compared to the reference product, which is important for ensuring therapeutic efficacy and safety in clinical use.

The clinical trial involves a study population comprising both **male** and **female** participants, with an age range categorized as **3**, which typically corresponds to adults. The trial is a bioavailability study conducted in **healthy subjects**, indicating that participants are generally in good health without underlying medical conditions. The sponsor has not provided the total number of participants involved in the study. The trial population selection criteria include both genders and consider vulnerable populations, although specific inclusion or exclusion criteria have not been disclosed. Lifestyle factors such as diet, physical activity, and habits are not specified in the available data. The sponsor has not provided further details regarding the selection process or additional demographic characteristics of the participants.

The clinical trial is designed as an **open-label**, randomized, crossover, two-period, two-sequence, single-dose study. It aims to assess the relative bioavailability of a **Rotigotine** 4.5 mg (2 mg/24 hrs) transdermal patch compared to the Neupro® 2 mg/24 h transdermal patch in 48 healthy adult volunteers under fasting conditions. The trial is categorized as a Phase 2 study and is expected to commence recruitment on September 30, 2024, with an estimated completion date of October 14, 2024. The study does not target any specific medical condition, as it is a bioavailability study conducted in healthy subjects.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful screening, participants will be randomized into one of two sequences for the crossover design. Each participant will receive both the test and reference products in separate periods, with a washout phase in between to prevent carryover effects. The study will include follow-up visits to monitor safety and collect pharmacokinetic data. The end-of-study visit will conclude the trial, where final assessments will be conducted, and data will be collected for analysis.

The expected length of participant involvement is approximately two weeks, including the washout period. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is structured to ensure rigorous data collection and analysis, adhering to ethical standards and regulatory requirements.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of this data limits the ability to describe the treatments comprehensively.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to begin recruitment on September 30, 2024, with an estimated end date of October 14, 2024. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous clinical standards to evaluate the therapeutic impact of the intervention under investigation. The trial's design and execution will be aligned with the regulatory requirements for Phase 2 studies, focusing on the efficacy and safety of the treatment. The results will contribute to the understanding of the treatment's potential benefits and inform future research directions.